InvestorsHub Logo
Followers 53
Posts 1010
Boards Moderated 0
Alias Born 06/12/2012

Re: DutchBlood_7 post# 2072

Monday, 01/13/2020 4:20:39 AM

Monday, January 13, 2020 4:20:39 AM

Post# of 3140
HMA treatments are definitely archaic and lacking in efficacy. I work in acute myeloid leukemia treatment research, and so much of the field is still trying to figure out the best therapeutic targets. MDS can progress to AML in many cases so I’ve studied MDS extensively. It’s a no brainer that Onconova will meet their endpoint of higher overall patient survival with rigosertib compared to HMAs, IMO. Ras inhibition should play out nicely for them given results in previous nonhuman models.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONTX News